Targeting CD47 in MDS and AML: An Emerging New Immunotherapy Approach

Gain expert insights on emerging treatment options targeting CD47 for myelodysplastic syndromes and acute myeloid leukemia with a downloadable slideset from a satellite symposium, an on-demand webcast, and an expert commentary.

Share

Program Content

Activities

HMA Combos in AML and HR-MDS
The Evolving Treatment of AML and Higher-risk MDS: HMA Combinations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Immunotherapy in AML and MDS
Targeting the Immune System in AML and MDS
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Targeting CD47 in AML and MDS
Evidence on Targeting CD47 in AML and MDS
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Activities

CD47 Therapy in MDS and AML
Targeting CD47 in MDS and AML: An Emerging New Immunotherapy Approach
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2023

Expires: August 14, 2024

Activities

CD47 Therapy in MDS and AML
Experts Address Questions on Therapeutic Targeting of CD47 in MDS and AML
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 19, 2023

Faculty

cover img faculity

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Michael Heuser, MD

Chair for Molecular Therapies in Hematology
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School
Hannover, Germany

cover img faculity

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.